Peter Altman, President and CEO of BioCardia, Inc., has made a notable move by purchasing 500 shares of the company’s stock. This acquisition, reported in a recent SEC filing, is valued at approximately $0.95 per share. Such transactions are often seen as a sign of confidence in a company’s prospects, particularly from its leadership.
BioCardia, Inc. operates in the biological products sector, specifically focusing on innovative therapies. The recent stock purchases by Altman may indicate his belief in the company's potential for growth and success in a competitive market.
Background
BioCardia, Inc. is a company incorporated in Delaware, primarily engaged in the biological products industry. Its Central Index Key (CIK) is 0000925741, and it trades under the symbol BCDA. The company has undergone several name changes in its history, with its current name established in 2011. The latest filing, dated October 20, 2026, is a Form 4, indicating insider transactions.
What the Filing Says
The SEC filing details two transactions made by Altman. On October 15, 2026, he acquired 200 shares, and on October 16, 2026, he purchased an additional 300 shares. Both transactions were executed at a price of $0.95 per share, with the total shares owned by Altman increasing to 385,385 following these acquisitions. The filing states, "This transaction was executed in multiple trades ranging from $0.94 to $0.95 per share."
Impact
These stock purchases may impact various stakeholders, including investors and employees of BioCardia. Altman's actions could be interpreted as a positive signal, potentially influencing investor sentiment and confidence in the company’s direction. With Altman's continued investment, employees may also feel reassured about the company's stability and future prospects.
What's Next
The filing does not say what happens next.